Trial record 1 of 1 for:    00534118
Previous Study | Return to List | Next Study

Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Roswell Park Cancer Institute
ClinicalTrials.gov Identifier:
NCT00534118
First received: September 20, 2007
Last updated: April 15, 2014
Last verified: April 2014

September 20, 2007
April 15, 2014
October 2003
May 2014   (final data collection date for primary outcome measure)
  • Determine if response rate exceeds 10% [ Time Frame: Every 2 weeks ] [ Designated as safety issue: No ]
  • Estimate the complete Response rate [ Time Frame: Every 2 weeks ] [ Designated as safety issue: No ]
  • Duration of response [ Time Frame: Every 2 weeks ] [ Designated as safety issue: No ]
  • Percent of complete responses
  • Response rate
  • Duration of response
Complete list of historical versions of study NCT00534118 on ClinicalTrials.gov Archive Site
Assess toxicity of cellular therapy [ Time Frame: Every 2 weeks ] [ Designated as safety issue: Yes ]
Toxicity
Not Provided
Not Provided
 
Donor Lymphocyte Infusion in Treating Patients With Recurrent or Persistent Hematologic Cancer After Donor Stem Cell Transplant
Cellular Infusions in Patients With Recurrent or Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplant

RATIONALE: Giving an infusion of donor lymphocytes may be able to kill cancer cells in patients with hematologic cancer that has come back after a donor stem cell transplant.

PURPOSE: This clinical trial is studying how well donor lymphocyte infusion works in treating patients with recurrent or persistent hematologic cancer after donor stem cell transplant.

OBJECTIVES:

Primary

  • Determine if the complete response rate exceeds 10% in patients with recurrent or persistent hematologic malignancies treated with donor lymphocyte infusion.

Secondary

  • Estimate the complete response rate in these patients.
  • Assess the toxicity of donor lymphocyte infusion in these patients.

OUTLINE: Patients receive up to four donor lymphocyte infusions at least 1 month apart in the absence of disease progression, unacceptable toxicity, or uncontrolled graft-versus-host disease.

Interventional
Not Provided
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
  • Leukemia
  • Lymphoma
  • Multiple Myeloma and Plasma Cell Neoplasm
  • Myelodysplastic Syndromes
Biological: donor lymphocytes
Given IV
Experimental: Infusion
Patients receive up to four donor lymphocyte infusions at least 1 month apart in the absence of disease progression, unacceptable toxicity, or uncontrolled graft-versus-host disease
Intervention: Biological: donor lymphocytes
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
39
Not Provided
May 2014   (final data collection date for primary outcome measure)

DISEASE CHARACTERISTICS:

  • Has undergone allogeneic stem cell transplantation (ASCT) for hematologic malignancy at least 30 days ago

    • No failure to engraft following transplant
    • No active acute or chronic graft-versus-host disease (GVHD)

      • Minimal GVHD allowed
  • Persistent or relapsed disease after ASCT, including 1 of the following:

    • Chronic myelogenous leukemia (CML), meeting any of the following criteria:

      • Molecular relapse (may be treated with imatinib mesylate after transplant), as defined by any of the following:

        • ASCT was non-T-cell depleted, a negative bcr/abl was documented by PCR post-transplant, and bcr/abl is now detectable by 2 consecutive PCR determinations > 30 days apart
        • ASCT was non-T-cell depleted and bcr/abl is detectable by PCR at any time after day 180 post-transplant
      • Cytogenetic relapse after 3-6 months of imatinib mesylate
      • Relapsed chronic phase, accelerated phase, or blastic phase CML after 3-6 months of imatinib mesylate

        • Must currently be in chronic phase or accelerated phase CML only
        • Patients with blastic phase CML must attain a second chronic phase
    • Acute myeloid leukemia, acute lymphoblastic leukemia, or myelodysplastic syndromes, meeting any of the following criteria:

      • Molecular relapse, as evidenced by < 5% blasts in the bone marrow and the patient's leukemia-specific molecular abnormality detectable by PCR
      • Cytogenetic relapse, as evidenced by < 5% blasts in the bone marrow and the patient's leukemia-specific chromosome abnormality detectable by standard cytogenetics at any time after day 60 post-transplant
      • Hematologic relapse, as evidenced by > 20% blasts in bone marrow or soft tissue recurrence

        • Must be treated with chemotherapy after transplant, but before study donor lymphocyte infusion (DLI)
    • Multiple myeloma

      • Relapsed disease or recurrence of M-protein after thalidomide or other salvage treatment

        • Prior post-transplant documentation of disappearance of M-protein by immunofixation
      • Residual or progressive disease
      • Rising M-protein level at any time post-transplant (measured at 3-month intervals)
      • Original M-protein detectable at 6 months post-transplant
      • Immune protein electrophoresis (IPEP) is required to show that M-component is the same on day 60 post-transplant as pre-transplant
      • Residual (> 5%) plasma cells in bone marrow
    • Relapsed non-Hodgkin lymphoma or Hodgkin lymphoma

      • Relapse or progression of disease must be evidenced within 3 months prior to donor lymphocyte infusion by physical exam, radiographic studies, or molecular studies

        • Tumor should be re-biopsied to determine histology
      • If Epstein-Barr virus (EBV) lymphoma is suspected, peripheral blood must be assayed for EBV genome (i.e., EBV DNA testing by PCR) within the past 30 days
    • EBV infection with associated pancytopenia

      • Persistent or refractory pancytopenia with EBV genome detected by PCR in the peripheral blood

        • Refractory pancytopenia is defined as pancytopenia that is poorly responsive to growth factors and/or transfusions
    • EBV lymphoproliferative disorder

      • Clonal lymphadenopathy that is refractory to standard therapy with acyclovir and immunoglobulin (DLI may be given with rituximab)
  • Not a candidate for repeat ASCT

    • Chimerism status is not required for determining eligibility for DLI
  • Patients eligible for allogeneic ASCT, but for whom DLI is offered as the first option, should have full donor chimerism at relapse or after therapy for relapsed disease
  • Patients with relapsed underlying disease after transplant who achieved remission after chemotherapy are allowed
  • No CNS recurrence that is not cleared by standard chemotherapy

    • CNS remission status must be maintained for 2 weeks
  • Original hematopoietic progenitor stem cell donor must be available for cell donation

    • No syngeneic donors

PATIENT CHARACTERISTICS:

  • Karnofsky performance status 60-100%
  • Life expectancy ≥ 8 weeks
  • Creatinine < 3 mg/dL
  • ABO/Rh and CMV IgG/IgM status known
  • No HIV1 and HIV2 antibody
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 3 months (males) or 6 months (females) after completion of study treatment

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
Both
up to 76 Years
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00534118
CDR0000564827, RPCI-I-00703
Yes
Roswell Park Cancer Institute
Roswell Park Cancer Institute
Not Provided
Principal Investigator: Philip L. McCarthy, MD Roswell Park Cancer Institute
Roswell Park Cancer Institute
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP